Radiotherapy in High-Burden Hormone-Sensitive Metastatic Prostate Cancer: Can It Be Useful?
/in Review/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- UPDATE: TD001 a New Potent ADC for Prostate Cancer Expressing PSMA Enters Phase 1/2 December 6, 2025
- PROSTest: Blood mRNA Assay Predicts 177Lu-PSMA Success in mCRPC After One Cycle December 4, 2025
- REVELUTION Trial: GnRH Antagonists Show Less Coronary Plaque Progression Than Agonists in Prostate Cancer ADT December 4, 2025
- Triaptosis: a New Way to Kill Cancer Using Menadione December 3, 2025
